Please login to the form below

Not currently logged in
Email:
Password:

Pills to fight obesity available OTC

GSK's Alli will be available to adults with a body mass index (BMI) of 28 or over, over the counter this week

GlaxoSmithKline's (GSK) Alli (Orlistat) will be available to adults with a body mass index (BMI) of 28 or over, over the counter this week. It is claimed that users will be able to shed 3lb a week, equivalent to more than three stones over a four-month period.

Alli works by absorbing approximately 25 per cent of the fat from food, thereby preventing it being turned into extra pounds by the body. The undigested fat passes straight through the body, creating "an urgent need to go to the bathroom".

However, according to a report in the Telegraph, Gareth Williams, professor of medicine at the University of Bristol and the author of Obesity: Science To Practice, has said Alli's side-effects are so severe that "possibly few users will even finish their first pack, let alone buy a second".

More seriously, he added: "The drug may cause only a small and transient downward blip in the otherwise inexorable climb in weight."

"Selling anti-obesity drugs over the counter will perpetuate the myth that obesity can be fixed simply by popping a pill and could further undermine efforts to promote healthy living, which is the only long-term escape from obesity," Prof Williams wrote in the British Medical Journal.

Profession Williams cautioned that real-life weight loss may not be as dramatic as in clinical trials, which showed that adding Alli to a reduced calorie, lower fat diet can help people lose 50 per cent more fat than dieting alone.

Alli costs £1.60 a day and is a diluted version of the prescription-only drug Xenical.

20th April 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics